Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug
NEW YORK, December 31, 2025, 13:38 ET — Regular session Vanda Pharmaceuticals shares jumped 28.1% to $9.01 at 1:38 p.m. ET on Wednesday after the company said the U.S. Food and Drug Administration approved Nereus (tradipitant) to prevent vomiting induced by motion. Vanda said the oral drug is a neurokinin-1 (NK-1) receptor antagonist — meaning it blocks a receptor involved…